May 30
0
Vanda Pharmaceuticals’ VEC-162 Demonstrates Positive Results In A Phase III Transient Insomnia Clinical Trial
Posted in Uncategorized by admin
Vanda Pharmaceuticals
Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development
and commercialization of clinical-stage product candidates for central
nervous system disorders, today announced positive top-line results from
the company’s Phase III clinical trial evaluating VEC-162, a balanced
melatonin receptor agonist, in transient insomnia. VEC-162 demonstrated
statistically significant improvements at all three tested doses compared
to placebo (p
Recent Posts
- Erectile Dysfunction Might Be Associated With Chronic Periodontal Disease: Two Ends Of The Cardiovascular Spectrum
- When A Sneeze Is Enough To Break A Bone
- Study pinpoints schizophrenia brain glitch
- Elderly Residents Need More Nurses, Australia
- Stem Cell Treatment Is Effective For Certain Cases Of Acute Leukemia
Archives
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010